JVDI Advertisement
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Journal of Veterinary Diagnostic Investigation Vol. 21 Issue 2, 214-219
Copyright © 2009 by the American Association of Veterinary Laboratory Diagnosticians
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tecles, F.
Right arrow Articles by Cerón, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tecles, F.
Right arrow Articles by Cerón, J. J.

Full Scientific Reports

Serum acute phase protein concentrations in female dogs with mammary tumors

Fernando Tecles, Marco Caldín, Anna Zanella, Francisco Membiela, Asta Tvarijonaviciute, Silvia Martínez Subiela and José Joaquín Cerón1

Correspondence: 1Corresponding Author: José Joaquín Cerón, Animal Medicine and Surgery Department, School of Veterinary Medicine, University of Murcia, Campus Espinardo s/n 30100 Espinardo, Murcia, Spain, e-mail: jjceron{at}um.es


   Abstract
TOP
 Sources and manufacturers
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Acute phase proteins (APPs) are proteins whose concentrations in serum change after any inflammatory stimulus or tissue damage. The aim of the current study was to evaluate 3 positive APPs (C-reactive protein, serum amyloid A, and haptoglobin) and 1 negative APP (albumin) in female dogs with mammary neoplasia. Acute phase proteins were studied in 70 female dogs aged 8–12 years in the following groups: healthy (n = 10); mammary tumors in stages I (n = 19), II (n = 5), III (n = 6), IV (n = 5), and V (n = 7); and with mammary neoplasia plus a concomitant disease (n = 18). In animals with mammary neoplasia, significant increases of positive APPs were only detected in those that had metastasis or a neoplasm with a diameter greater than 5 cm and ulceration. Dogs with mammary neoplasia and a concomitant disease also had high C-reactive protein concentrations. Albumin concentration was decreased in animals with metastasis and with a concomitant disease. The results of the present study indicate that the acute phase response could be stimulated in female dogs with mammary gland tumors because of different factors, such as metastasis, large size of the primary mass, and ulceration or secondary inflammation of the neoplasm.

Key Words: Albumin • C-reactive protein • dogs • haptoglobin • mammary tumor • serum amyloid A


   Introduction
TOP
 Sources and manufacturers
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Mammary tumors are one of the most prevalent types of neoplasm in female dogs,15 occurring mostly in countries where dogs are not routinely spayed at an early age.18 Mammary tumors can represent up to 52% of all tumors in female dogs,3 with 41–53% of tumors diagnosed as malignant. Malignant neoplasms may metastasize to local lymph nodes and internal organs, such as the lungs.15 Clinically, canine mammary tumors are classified using the TNM (tumor-node-metastasis) system devised by the World Health Organization.13,15 The TNM system also can be used to achieve offstage the severity of the neoplasm. Both the TNM system classification and staging provide valuable prognostic information that can be used to determine whether tumors can be adequately treated with local therapy or if they require an adjuvant treatment.16

Acute phase proteins (APPs) are serum proteins whose concentrations change as a part of an innate host defense system called acute phase response. Positive APPs increase in concentration after inflammation and can be divided into major and moderate APPs. Major APPs have an early, marked high rise in concentration followed by a rapid decline in concentration. Moderate APPs require more time to increase in concentration, usually show increases of less magnitude, and then return to reference intervals. In contrast, negative APPs decrease in concentration after an inflammatory stimulus.6 In dogs, causes of changes in APP serum concentrations include infectious, immunologic, traumatic, or neoplastic diseases.5 Increased concentrations of positive APPs, such as C-reactive protein (CRP) and serum amyloid A (SAA), have been found in dogs with lymphoma and other hematologic malignancies.7,8,17 Measurements of APPs can be used as a screening test for systemic response to an inflammatory stimulus and may be helpful to assess clinical progression and to monitor treatment of some neoplastic diseases.17

Many reports can be found in human literature where APPs have been extensively studied in breast cancer at different stages and clinical presentations.11,12,18,21 However, similar information is not available regarding APPs and mammary tumors in female dogs. The purpose of this study was to analyze the serum concentrations of the main positive and negative APPs (CRP, SAA, haptoglobin [Hp], and albumin) in female dogs with mammary neoplasia to better understand the concentrations of APPs with regard to the clinical stage of mammary neoplasia.


   Materials and Methods
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals
Sixty female dogs between 8 and 12 years of age with a clinical history of mammary masses were studied. These animals were patients from the San Marco Veterinary Hospital (Padova, Italy), different veterinary clinics in southern Spain, or the Veterinary Teaching Hospital of the University of Murcia (Murcia, Spain). Each patient had a physical examination with additional evaluation of the size of the neoplasm and the presence or absence of ulceration. A complete blood cell count, serum biochemical profile, serum protein electrophoresis, blood gas analysis, and urinalysis (with bacterial culture if needed) were performed to detect or exclude any concurrent disease. Inguinal and axillary lymph nodes also were examined, and biopsies were taken during tumor surgery if lymph node metastases were suspected. If distant metastases were suspected, radiography, ultrasonography, and multidetector computerized tomography were used to detect these lesions. Biopsies of the neoplastic masses were obtained prior to or after surgery for a definitive diagnosis of mammary neoplasia. Biopsy specimens were fixed in 10% neutral buffered formalin solution, processed routinely, embedded in paraffin sections, stained with hematoxylin and eosin, and coverslipped. Tissue sections were evaluated by pathologists to determine the histologic type and degree of malignancy of all tumors. Histologic type was determined following World Health Organization criteria.9

Recorded data regarding tumor size, lymph node involvement, and metastasis were used to classify tumors according to the TNM system. Subsequent staging (stages I–V) of the neoplasms was based on the criteria in Table 1. Concurrent diseases, such as pyometra, mastitis, or other inflammatory diseases, were observed in 18 dogs that were grouped separately (concomitant disease group).


View this table:
[in this window]
[in a new window]

  		Table 1 Staging of canine mammary tumors (excluding inflammatory carcinoma) modified from the World Health Organization.*,13,15

 
The control group consisted of ten 8–12-year-old female German Shorthaired Pointers that were housed in the Animal Resources Centre Service of the University of Murcia. These dogs were determined to be healthy after physical examination and laboratory testing. All hematologic, serum biochemical, and urinalysis test results were within the reference intervals established at the authors' laboratory (Murcia Laboratory).

Specimen Collection
Blood samples for APP determination were obtained by venipuncture of cephalic vein at the time of clinical diagnosis and prior to any treatment. The blood was divided and placed in tubes containing ethylenediamine tetraacetic acida (EDTA) and clotting activator.b EDTA-anticoagulated samples were used for complete hematologic analysis on the day of collection. Tubes with clotting activator were used for serum APP determination. These specimens were allowed to clot for 30 min and then centrifugedc at 3,000 x g for 10 min. The serum was collected, placed in a new tube, and frozen. All samples were transported on dry ice to the Animal Medicine and Surgery Department (University of Murcia), where they were stored at –20°C until analysis.

App Analysis
Serum Hp concentration was determined by a commercially available kitd in an automated analyzer.e C-reactive protein and SAA concentrations were determined using a solid-phase sandwich enzyme-linked immunosorbent assayd according to the manufacturer's instructions; absorbance was measured at a wavelength of 450 nm using a microtiter plate reader.f Albumin concentration was determined by the bromocresol green dye–binding method using a commercial kit.g All these methods had previously been validated for use with canine samples (Martínez-Subiela S, Tecles F, Parra MD, Cerón JJ: 2003, Analytical validation of different methods for determination of main acute phase proteins in canine serum samples. In: Proceedings of the 4th European Colloquium on Acute Phase Proteins, p. 142. Segovia, Spain). In order to avoid high interassay coefficients of variation, all samples were analyzed in a single run.

Statistical Analyses
Descriptive statistics were calculated using a spreadsheet,h whereas statistical analyses were performed using a statistical computer application.i Kolmogorov–Smirnov's test was performed to assess normality of data, giving a nonparametric distribution. Data was log-transformed to assume Gaussian distribution and variance homogeneity. Concentrations of each APP were statistically compared with different clinical aspects of disease, including 1) the clinical stage of disease (stage I, II, III, IV, or V) and presence of concomitant disease (CD), 2) histologic malignancy in which cases were grouped as benign tumors (B), malignant tumors without metastasis (M), or malignant tumors with metastasis (MT), and 3) tumor size designated as nonulcerated masses less than 3 cm in diameter (T1), nonulcerated masses between 3 and 5 cm in diameter (T2), nonulcerated masses with diameter greater than 5 cm (T3a), or ulcerated masses with diameter greater than 5 cm (T3b). In each statistical approach, the group of healthy dogs served as the control group. Groups were analyzed by analysis of variance, and significant differences between group means were located with Tukey's test. The level of significance tested was P < 0.05.


   Results
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Clinical Data
Tumor staging, histologic diagnosis, and concurrent diseases detected are shown in Table 2. For the group of 42 dogs with mammary masses and no concurrent disease, 12 dogs had evidence of metastasis (stages IV and V), and 10 of these individuals had ulcerated masses.


View this table:
[in this window]
[in a new window]

  		Table 2 Dogs with mammary tumors grouped by clinical stage of disease.

 
Relationship between Serum App Concentrations and the Clinical Stage of the Disease
The APP concentrations obtained for each group are shown in Table 3. No differences in CRP concentration were detected between healthy animals and dogs with nonmetastatic mammary neoplasia. Dogs with mammary tumors at stages IV and V and a CD had a significant increase in serum CRP concentration when compared with healthy animals and dogs with stage I and stage II neoplasia. Serum amyloid A concentration was significantly increased in dogs with stage IV mammary neoplasia when compared with healthy animals and dogs with stages I, II, and III neoplasia. Serum amyloid A concentration also was significantly increased in dogs with stage V mammary neoplasia when compared with dogs with stage I or II neoplasia. No statistically significant differences were found between groups for Hp concentration. Albumin concentration decreased significantly in dogs with inflammatory conditions when compared with dogs that had stage I or II mammary neoplasia.


View this table:
[in this window]
[in a new window]

  		Table 3 Median serum concentrations (25th–75th percentiles) of acute phase proteins of healthy dogs and dogs with mammary tumors in different clinical stages of disease.*

 
Relationship between Serum App Concentrations and Malignancy
The results obtained for each group are shown in Table 4. Dogs with metastasis had a significant increase in CRP, SAA, and Hp concentrations compared with healthy animals and dogs with mammary tumors without metastasis. Using the reference interval from the authors' laboratory (0.15–12 mg/l for CRP, 0.79–5 mg/l for SAA, and 0.02–3 g/l for Hp; unpublished results from Murcia Laboratory), serum concentrations of CRP, SAA, and Hp were within the reference interval in 73.3%, 96.6%, and 72.0% of patients with limited disease, respectively. In animals with metastatic disease, serum concentrations of CRP, SAA, and Hp were within the reference interval for 23.0%, 27.3%, and 27.3% of patients, respectively. Albumin concentration was significantly decreased in dogs with metastasis compared with dogs without metastasis. No differences in APPs were found between benign and malignant tumors without metastasis.


View this table:
[in this window]
[in a new window]

  		Table 4 Median serum concentrations (25th–75th percentiles) of acute phase proteins in healthy dogs and dogs with mammary tumors classified by histologic evidence of malignancy.*

 
Relationship Between Serum App Concentrations and Tumor Size
The results obtained for each group are shown in Table 5. C-reactive protein concentration was increased in dogs with tumors greater than 5 cm in diameter when compared with healthy animals. The highest CRP concentrations were found in dogs with ulcerated tumors (T3b group). Serum amyloid A concentration was only significantly increased in dogs with ulcerated tumors. No differences were observed in Hp concentration between the groups. Lower albumin concentrations were observed in the CD group when compared with T1.


View this table:
[in this window]
[in a new window]

  		Table 5 Median serum concentrations (25th–75th percentiles) of acute phase proteins in dogs with mammary tumors compared with the size of the neoplasm.*

 

   Discussion
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
An analytic profile of different APPs was used in the current study, including 2 major positive APPs (CRP and SAA), 1 moderate positive APP (Hp), and 1 negative APP (albumin). Measurement of an APP profile or a serum APP profile may be more meaningful than making observations of a single protein. Specifically, the use of APP profiles that quantitate at least 1 major and 1 moderate APP are preferred to the determination of individual APPs.5

In animals with mammary neoplasia, significant increases of CRP and SAA concentration were only detected in those dogs that had metastasis or a tumor diameter greater than 5 cm and ulceration. Although it is unknown why stage IV tumors had higher APP concentrations than stage V tumors, factors that could influence the magnitude of the acute phase response of tumors in stages IV and V (e.g., individual variation) should be further studied. Female dogs with stages I–III neoplasia had a poor acute phase response. Similar findings have been described in human patients with breast carcinoma.12,14 Results would suggest that, as described in humans, mammary tumors are poor stimuli for the production of APPs in the absence of metastasis and secondary inflammation or ulceration.

When female dogs with mammary tumors were grouped according to the degree of malignancy of the neoplasm, a significant increase in concentration of all positive APPs studied, especially in CRP and SAA, was found in dogs with metastasis. The relationship between the presence of metastasis and increased CRP concentration has been reported.4 C-reactive protein and SAA have greater increases in concentration in human patients with metastasis of breast carcinoma1,12,19 and in other neoplastic diseases.2 Tumor dissemination is described as a series of complex biologic processes that move tumor cells from the primary neoplasm to distant locations.20 Therefore, the increased concentrations of APPs observed in cases of metastasis could be due to the direct invasion and damage of tissues by neoplastic cells or due to inflammatory mediators released during this process. Another hypothesis is that dogs with metastasis could have a higher degree of immunosuppression, as has been previously described in humans.10 This would result in an increased incidence of secondary infections that would stimulate an acute phase response. Two dogs with metastasis that lacked ulceration had high concentrations of the 3 positive APPs and a low albumin concentration. This would support the hypothesis that an inflammatory reaction can be produced in dogs with metastasis without having a direct relationship to ulceration of the mass.

More than 70% of animals with metastasis had high APP concentrations when compared with dogs without metastasis (less than 30%). In humans with cancer, SAA concentration was within the reference interval in 70% of patients with limited disease compared with 44% of patients with metastasis.19 In addition, increases in SAA concentration have been associated with more advanced disease with other tumors.1,14 According to the present study, high CRP and/or SAA serum concentrations in a female dogs with mammary neoplasia that lack clinical signs of a concurrent inflammation could be clinically relevant. Further studies should be made to determine the sensitivity and specificity of SAA and CRP quantitation to detect possible metastasis in dogs with mammary neoplasia. It must be pointed out that the current APP study was not designed to detect early metastases or micrometastases. This should be accomplished by histologic examination of intraneoplastic or perineoplastic lymphatic vessels and immunohistochemical detection of tumor markers. Future studies of APPs in mammary neoplasia should clarify whether the presence of micrometastases could be responsible for high APP concentrations.

In the current study, the highest concentrations of CRP and SAA were observed in patients with ulcerated tumors. In humans, it has been reported that high CRP values were observed in response to mammary neoplasms that infiltrated skin or muscle. Furthermore, increased CRP concentrations were more pronounced if the mass was ulcerated.12 These observations could lead to the hypothesis that in cases of neoplasia, the magnitude of the acute phase response is related to the activity or mass of inflamed tissue, reflecting a nonspecific inflammatory response to tumor necrosis or to local tissue damage.

Female dogs with mammary tumor and CD showed significant increases in CRP concentration, even in those animals with stages I, II, and III of neoplasia. These results were expected, because most of the CDs are recognized causes of an acute phase response.5 The CD animals in the current study had a wide range of APP concentrations that could be explained by differences in the cause and severity of disease.

The results of the present study indicate that the acute phase response is stimulated in female dogs with mammary gland tumors because of factors such as metastasis, large size of the primary mass, and ulceration or secondary inflammation of the neoplasm. Further studies are desirable to assess the value of APP determination in the prognosis, efficacy of therapy, or recurrence of mammary tumors in female dogs.


   Sources and manufacturers
TOP
 Sources and manufacturers
Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 
From the Animal Medicine and Surgery Department, School of Veterinary Medicine, University of Murcia, Murcia, Spain (Tecles, Membiela, Tvarijonaviciute, Martínez Subiela, Cerón), and the San Marco Veterinary Hospital, Padova, Italy (Caldín, Zanella). Back

Vacutainer® EDTA K3 tubes, BD, Franklin Lakes, NJ. Back

Tapval, Aquisel SL, Barcelona, Spain. Back

Refrigerated Centrifuge Z 300 K, Hermle Labortechnik GmbH, Wehingen, Germany. Back

Tridelta Development Ltd., Maynooth, Ireland. Back

Cobas Mira PLUS, Horiba ABX, Montpellier, France. Back

PowerWave XS, BioTek Instruments Inc., Winooski, VT. Back

Spinreact SA, Gerona, Spain. Back

Microsoft Excel® for Windows, Microsoft Corporation, Silicon Valley, CA. Back

SPSS 15.0 for Windows, SPSS Inc., Chicago, IL. Back


   References
TOP
 Sources and manufacturers
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Biran H., Friedman N., Neumann L., et al. 1986 Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39 794 797.[Abstract/Free Full Text]
  2. Bolayirli M., Turna H., Orhanoglu T., et al. 2007 C-reactive protein as an acute-phase protein in cancer patients. Med Oncol 24 338 344.[Medline]
  3. Brody R.S., Goldschmidt M.H., Roszel J.R. 1985 Canine mammary gland neoplasia. J Am Anim Hosp Assoc 19 61 90.
  4. Caspi D., Snel F.W.J.J., Batt R.M., et al. 1987 C-reactive protein in dogs. Am J Vet Res 48 919 921.[Medline]
  5. Cerón J.J., Eckersall P.D., Martínez Subiela S. 2005 Acute-phase proteins in dogs and cats: current knowledge and future perspectives. Vet Clin Pathol 34 85 99.[Medline]
  6. Cerón J.J., Martínez Subiela S., Ohno K., Caldin M. 2008 A seven-point plan for acute-phase protein interpretation in companion animals. Vet J 177 6 7.[Medline]
  7. Merlo A., Rezende B.C., Franchini M.L., et al. 2008 Serum amyloid A is not a marker for relapse of multicentric lymphoma in dogs. Vet Clin Pathol 37 79 85.[Medline]
  8. Mischke R., Waterston M., Eckersall P.D. 2007 Changes in C-reactive protein and haptoglobin in dogs with lymphatic neoplasia. Vet J 174 188 192.[Medline]
  9. Misdorp W., Else R.W., Hellmén E., Lipscomb T.P. 1999 Histological classification of mammary tumors of the dog and cat. In: World Health Organization international histological classification of tumors of domestic animals Shulman F.I. 2nd series, vol. 7 1 59 Armed Forces Institute of Pathology Washington DC.
  10. Mohanty I., Nayak M., Nanda B.K. 1991 Cell mediated immune status in carcinoma breast. Indian J Pathol Microbiol 34 1 6.[Medline]
  11. Mortensen R.F., Rudczynski A.B. 1982 Prognostic significance of serum CRP levels and lymphoid cell infiltrates in human breast cancer. Oncology 39 129 133.[Medline]
  12. O'Hanlon D.M., Lynch J., Cormican M., Given H.F. 2002 The acute-phase response in breast carcinoma. Anticancer Res 22 1289 1293.[Medline]
  13. Owens L.N. 1980 Classification of tumors in domestic animals, 1st ed. VPH/CMO/80.20 World Health Organization Geneva, Switzerland.
  14. Raynes G.J., Cooper E.H. 1983 Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 36 798 803.[Abstract/Free Full Text]
  15. Rutteman G.R., Withrow S.J., MacEwen E.G. 2001 Tumors of the mammary gland. In: Small animal clinical oncology Withrow S.J., MacEwen E.G. 3rd ed. 445 477 WB Saunders Philadelphia, PA.
  16. Sorenmo K. 2003 Canine mammary gland tumors. Vet Clin North Am Small Anim Pract 33 573 596.[Medline]
  17. Tecles F., Spiranelli E., Bonfanti U., et al. 2005 Preliminary studies of serum acute-phase protein concentration in hematologic and neoplastic diseases of the dog. J Vet Intern Med 19 865 870.[Medline]
  18. Tesarová P., Kvasnicka J., Umlaufová A., et al. 2003 Proteiny akutní fáze u pacientek s karcinomem mammy [Acute-phase proteins in female patients with breast carcinoma]. Sb Lek 104 121 132. In Czech. Abstract in English.[Medline]
  19. Weinstein P.S., Skinner M., Sipe J.D., et al. 1984 acute-phase proteins or tumor markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19 193 198.[Medline]
  20. Zaidan M.L. 2008 The search for suitable prognostic markers for canine mammary tumors: a promising outlook. Vet J 177 3 5.[Medline]
  21. Zakrzewska I., Kozlowski L., Wojtukiewicz M. 2003 Ocena zmian stezen interleukiny 6 i bialka C-reaktywnego u chorych na nowotwory piersi [Assessment of changes in levels of interleukin 6 and C reactive protein in patients with breast tumors]. Pol Merkur Lekarski 15 115 117. In Polish. Abstract in English.[Medline]




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tecles, F.
Right arrow Articles by Cerón, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tecles, F.
Right arrow Articles by Cerón, J. J.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS